XML 98 R84.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]      
Net loss attributable to Adaptive Biotechnologies Corporation [1] $ (159,492) $ (225,250) $ (200,191)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 147,101,648 144,383,294 142,515,917
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (1.08) $ (1.56) $ (1.4)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 147,101,648 144,383,294 142,515,917
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (1.08) $ (1.56) $ (1.4)
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.